Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

13 results about "Mumpsvax" patented technology

Mumpsvax is a mumps vaccine made of mumps virus. Mumpsvax is a product of Merck & Co.,Inc. The vaccine is a component of Merck's three-virus MMR vaccine. Mumpsvax is administered by a subcutaneous injection of live virus reconstituted from freeze-dried vaccine. The dosage of the mumps vaccine component in MMR is the same as of Mumpsvax, "Each 0.5 mL dose contains not less than 20,000 TCID₅₀ of mumps virus." The Merck product information recommends MMR as the secondary vaccination treatment with Mumpsvax. Mumpsvax is produced from the Jeryl Lynn strain of mumps virus developed by Maurice Hilleman. When his daughter Jeryl Lynn Hilleman contracted Mumps Dr. Hilleman cultured the vaccine strain from her throat. The mumps virus strains were developed in embryonic hens' eggs and chick embryo cell cultures. The resulting strains of virus were less well-suited for human cells, and are thus said to be attenuated. They are sometimes referred to as neuroattenuated in the sense that these strains are less virulent to human neurons than the wild strains. The cells used in culture, virus stocks used, and animal fluids are all screened for extraneous material as part of the vaccine production.

Immunoglobulin G (IgG) antibody of parotitis virus, recombinant IgM antibody and application

The invention relates to the field of in-vitro immunodiagnosis detection, in particular to an IgG antibody of mumps virus, a recombinant IgM antibody and application. Wherein the IgG antibody comprises a heavy chain constant region, a light chain constant region, and a heavy chain variable region and a light chain variable region of the IgG monoclonal antibody which is specifically combined with the mumps virus, and the IgG monoclonal antibody is of a mouse source or a rabbit source. According to the present invention, the IgG antibody is modified to obtain the recombinant IgM antibody, and the IgG antibody and the recombinant IgM antibody are not only suitable for the chemiluminescence method, but also show the expected sensitivity amplification factor in other immunological detection methods, such that the low-abundance detection of the specifically bound mumps virus can be easily achieved.
Owner:INNOVITA BIOLOGICAL TECH CO LTD +1

F-genotype mumps virus attenuated strain and construction method therefor and application thereof

Provided are an F-genotype mumps virus attenuated strain, a construction method therefor and an application thereof. The attenuated strain is a mumps virus with the accession number of CCTCC NO: V201950. Further provided are a vaccine composition containing the F-genotype mumps virus attenuated strain as an active ingredient and a preparation method thereof.
Owner:SHANGHAI KING CELL BIOTECHNOLOGY CO LTD +1

Primer group for detecting mumps virus, application of primer group, kit and application of kit

The invention relates to the technical field of chemical synthesis and diagnostic reagents, in particular to a primer group for detecting mumps virus, application of the primer group, a kit and application of the kit. The mumps virus NCRs multiplex RT-PCR amplification method is established on the basis of a multiplex PCR principle, one tube for three detections is realized, amplification products of three non-coding regions of N-P, P-M and M-F are obtained through successful amplification, and a full-length sequence of the NCRs is obtained through sequence splicing. Based on the primer group, the invention provides the primer group for detecting the mumps virus NCRs. A gene sequence of mumps virus NCRs is analyzed by a bioinformatics method, and three groups of primers respectively aiming at three non-coding regions of N-P, P-M and M-F are synthesized by a chemical synthesis technology. The primer group provided by the invention can be used for identifying the MuV, can also be used for simultaneously detecting three non-coding region sequences of N-P, P-M and M-F of the MuV, and is used for molecular virology monitoring.
Owner:STATION OF VIRUS PREVENTION & CONTROL CHINA DISEASES PREVENTION & CONTROL CENT

Mumps and measles virus immunogens and their use

Embodiments of immunogens comprising a recombinant Mumps (MuV) F ectodomain trimer stabilized in a prefusion conformation or a recombinant Measles (MeV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also provided are embodiments of immunogens comprising chimeric proteins comprising the recombinant MuV or MeV F ectodomain trimer and one or more MuV HN or MeV H ectodomains. Also disclosed are nucleic acids encoding the immunogens and methods of their production. Methods for inducing an immune response in a subject by administering a disclosed immunogen to the subject are also provided. In some embodiments, the immune response treats or inhibits MuV and / or MeV infection in a subject.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

Gallid alphaherpesvirus 3 (MDV-2), a viral vector against different avian pathogens: a new vaccination strategy in the poultry industry

The present invention refers in general to the field of veterinary medicine and especially to the development of vectored vaccines using the Gallid alphaherpesvirus 3 (GaHV-3) or Marek's disease serotype 2 (MDV-2) vector, which contains protective antigens against different avian pathogens such as Newcastle disease virus (NDV), avian infectious laryngotracheitis virus (ILTV), infectious bursal disease virus (IBDV) or Gumboro disease virus, avian influenza virus (AIV), infectious bronchitis virus (IBV).
Owner:FARMACOLOGICOS VETERINARIOS S A C

A kit for detecting the pathogen of turtle mumps disease and its usage method

PendingCN122081455Amild dispersionPromote microsphere enrichmentSilicaMicrobiological testing/measurementDiseaseMicrosphere
This invention provides a kit for detecting the pathogen of turtle mumps disease and its usage method, belonging to the field of biodetection technology. The kit includes a tissue pathogen release buffer, magnetic macroporous SiO2 microspheres, nucleic acid extraction solution, and detection reagents for the turtle mumps disease pathogen. This invention uses the tissue pathogen release buffer to release pathogens from tissues, magnetic macroporous SiO2 microspheres for pathogen enrichment, and nucleic acid extraction reagents to obtain a crude extract that can be directly used for LAMP amplification and qPCR amplification detection.
Owner:SHAANXI NORMAL UNIV

Method for manufacturing viral vaccines and compositions thereof

Present invention provides a method of producing clarified virus pool of virus to obtain a lyophilized / freeze-dried live attenuated virus immunogenic composition / formulation comprising atleast one or more than one antigens / immunogens. Present invention provides a method of producing a clarified virus pool of viruses such as measles, mumps, rubella. It provides the improved large scale affordable / safe manufacturing processes (encompassing cultivation, purification & formulation stages) that utilize minimum animal origin components, provide high virus yield, ensure virus integrity / stability preservation across manufacturing & storage.
Owner:SERUM INST OF INDIA PTE LTD

Methods for preparing viral vaccines and compositions thereof

The present invention provides methods of producing clarified virus pools to obtain lyophilized / lyophilized live attenuated viral immunogenic compositions / formulations comprising at least one or more than one antigen / immunogen. The invention provides a method for producing clarified virus pools for viruses such as measles, parotitis, rubella and the like. The present invention provides an improved large-scale, burdenable / safe preparation process (encompassing culture, purification and formulation stages) that utilizes minimal animal-derived components, provides high viral yields, and ensures that the viruses maintain integrity / stability during preparation and storage.
Owner:SERUM INST OF INDIA PTE LTD

Immunogens of mumps virus and measles virus and their use

The present invention provides polypeptides, polynucleotides, and the like for inducing and detecting immune responses to mumps virus (MuV) and measles virus (MeV). [Solution] An embodiment of an immunogen is provided comprising a MuV F ectodomain trimer or a MeV F ectodomain trimer stabilized in a pre-fusion conformation. Also provided is an embodiment of an immunogen comprising a chimeric protein comprising the recombinant MuV or MeV F ectodomain trimer and one or more MuV HN or MeV H ectodomains. Also disclosed are nucleic acids encoding the immunogen and methods for producing them. Methods for inducing an immune response in a subject by administering the immunogen of this disclosure are also provided. In some embodiments, the immune response treats or inhibits MuV infection and / or MeV infection in the subject.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

Mumps virus and measles virus immunogens and their uses

Immunogen embodiments are provided that include a recombinant mumps (MuV) F ectodomain trimer stabilized in a prefusion conformation or a recombinant measles (MeV) F ectodomain trimer stabilized in a prefusion conformation. Also provided are immunogen embodiments that include a chimeric protein comprising the recombinant MuV or MeV F ectodomain trimer and one or more MuV HN or MeV H ectodomains. Nucleic acids encoding the immunogens and methods for their production are also disclosed. Methods for inducing an immune response in a subject by administering an immunogen of the present disclosure to the subject are also provided. In some embodiments, the immune response treats or inhibits MuV and / or MeV infection in the subject. TIFF2023506170000066.tif98128
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

Measles-mumps-rubella (MMR) vaccines

PCT designated stageWO2026013289A1SsRNA viruses negative-senseSsRNA viruses positive-senseAntigenMeasles virus IgG
The application generally relates to recombinant genetic constructs comprising a recombinant measles virus expressing at least one rubella virus polypeptide, protein, antigen, or antigenic fragment thereof, and one mumps virus polypeptide, protein, antigen, or antigenic fragment. The application also relates to the uses of genetic constructs or viruses, and more particularly their applications for inducing immune responses and protection against rubella infection, mumps infection, and measles infection.
Owner:INST PASTEUR +1